Nectar Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 532649 | NSE: NECLIFE | Pharmaceuticals & Drugs | Small Cap

Nectar Lifesciences Share Price

37.85 1.79 4.96%
as on 31-Oct'24 16:01

DeciZen - make an informed investing decision on Nectar Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Nectar Lifesciences stock performance -

mw4me loader
P/E Ratio (SA):
136.18
Market Cap:
837.6 Cr.
52-wk low:
22.7
52-wk high:
56.4

Is Nectar Lifesciences Ltd an attractive stock to invest in?

1. Is Nectar Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nectar Lifesciences Ltd is a average quality company.

2. Is Nectar Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Nectar Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Nectar Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nectar Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Nectar Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nectar Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 11.6%10%9.7%9.1%10.3%8.2%1.4%5.8%2.6%6.5%-
Value Creation
Index
-0.2-0.3-0.3-0.4-0.3-0.4-0.9-0.6-0.8-0.5-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,6441,6761,6431,8762,7852,3631,5421,6681,5241,6841,649
Sales YoY Gr.-2%-2%14.1%48.5%-15.2%-34.8%8.2%-8.7%10.5%-
Adj EPS 32.42.42.32.11.3-2.50.8-2.6-0.10.3
YoY Gr.--17.6%-0.4%-3.7%-9%-37.3%-285.7%NA-406%NA-
BVPS (₹) 41.142.644.947.249.350.647.348.547.547.747.8
Adj Net
Profit
66.254.454.352.247.529.9-55.418.7-57.7-26
Cash Flow from Ops. 14416919965.123928621.395133225-
Debt/CF from Ops. 6.45.74.414.73.82.742.49.15.72.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 0.3%-9.6%3%10.5%
Adj EPS -167.9%-153.2%NANA
BVPS1.7%-0.7%0.3%0.4%
Share Price 0.1% 21.3% 12.8% 64.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
75.75.55.14.42.7-51.7-5.4-0.20.6
Op. Profit
Mgn %
16.214.313.612.69.59.26.69.53.699.5
Net Profit
Mgn %
43.33.32.81.71.3-3.61.1-3.8-0.10.4
Debt to
Equity
110.90.90.80.70.90.80.70.6-
Working Cap
Days
285298324292206240330288310272134
Cash Conv.
Cycle
13414215313310411513210812610934

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.60%

Debt to equity has declined versus last 3 years average to 0.59

Sales growth has been subdued in last 3 years 2.99%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 9.56%

Latest Financials - Nectar Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 0.3 0.3
TTM Sales (₹ Cr.) 1,649 1,649
BVPS (₹.) 47.8 47.8
Reserves (₹ Cr.) 1,050 1,050
P/BV 0.78 0.78
PE 136.18 136.35
From the Market
52 Week Low / High (₹) 22.72 / 56.39
All Time Low / High (₹) 7.20 / 60.90
Market Cap (₹ Cr.) 838
Equity (₹ Cr.) 22.4
Face Value (₹) 1
Industry PE 46.8

Management X-Ray of Nectar Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Nectar Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales1,6441,6761,6431,8762,7852,3631,5421,6681,5241,684
Operating Expenses 1,3771,4371,4191,6392,5212,1451,4401,5091,4691,533
Manufacturing Costs117127129145154140129147173186
Material Costs1,1411,1751,1541,3662,2211,8581,1561,2221,1591,202
Employee Cost 59787675777871727582
Other Costs 60576154696985686263
Operating Profit 26723922423626421810215955152
Operating Profit Margin (%) 16.2%14.2%13.6%12.6%9.5%9.2%6.6%9.5%3.6%9.0%
Other Income 2062366411115324
Interest 126123117115148126112798997
Depreciation 77576264636160575961
Exceptional Items 000000-25000
Profit Before Tax 856467635936-8534-4118
Tax 18101210116-129-1813
Profit After Tax 665455524730-7325-225
PAT Margin (%) 4.0%3.2%3.4%2.8%1.7%1.3%-4.7%1.5%-1.5%0.3%
Adjusted EPS (₹)3.02.42.52.32.11.3-3.31.1-1.00.2
Dividend Payout Ratio (%)3%4%2%2%2%4%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 9589541,0071,0591,1051,1351,0611,0871,0651,069
Share Capital 22222222222222222222
Reserves 9369329841,0361,0821,1121,0381,0641,0421,047
Minority Interest0000000000
Debt861873794854802741840794685553
Long Term Debt266245164220166121128291226140
Short Term Debt595627630634636620712503459412
Trade Payables456497528539483527342377319420
Others Liabilities 236233252272315229132130100142
Total Liabilities 2,5102,5572,5812,7242,7042,6322,3752,3872,1692,184

Fixed Assets

Gross Block1,4511,3841,3641,4561,4901,5091,5561,5631,5581,599
Accumulated Depreciation518478482604666724784840896957
Net Fixed Assets934906881852825785772723662643
CWIP 919910210010011599857866
Investments 1111111111
Inventories791836854859915975587660673709
Trade Receivables446492500612561397375447280379
Cash Equivalents 3336139212125181820
Others Assets214186229290282338516454459366
Total Assets 2,5102,5572,5812,7242,7042,6322,3752,3872,1692,184

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 144169199652392862195133225
PBT 856567635936-8534-4118
Adjustment 18517415917620718814812597138
Changes in Working Capital -119-62-20-161-1372-39-657769
Tax Paid -6-9-7-13-14-9-4000
Cash Flow From Investing Activity -60-77-18-29-26-33-291752-17
Capex -80-82-25-33-36-36-311550-29
Net Investments 0-100000010
Others 2167310332212
Cash Flow From Financing Activity -61-89-204-40-201-25211-119-186-205
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 00000000-62-72
Interest Paid -126-123-117-115-148-126-112-79-79-87
Dividend Paid -2-3-3-1-1-1-1000
Others 6637-8477-52-125125-41-44-47
Net Cash Flow 233-24-41214-802
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)7.175.795.625.054.382.68-6.662.36-2.090.47
ROCE (%)11.589.959.719.1210.288.241.415.792.586.54
Asset Turnover Ratio0.710.710.680.791.150.990.70.810.770.88
PAT to CFO Conversion(x)2.183.133.621.255.099.53N/A3.8N/A45
Working Capital Days
Receivable Days869610497696680787662
Inventory Days162166177149104131162118139131
Payable Days1431481621438499137107109112

Nectar Lifesciences Ltd Stock News

Nectar Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Nectar Lifesciences on 31-Oct-2024 16:01 is ₹37.85.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Nectar Lifesciences stood at ₹837.6.
The latest P/E ratio of Nectar Lifesciences as of 31-Oct-2024 16:01 is 136.2.
The latest P/B ratio of Nectar Lifesciences as of 31-Oct-2024 16:01 is 0.78.
The 52-week high of Nectar Lifesciences is ₹56.39 and the 52-week low is ₹22.72.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Nectar Lifesciences is ₹1,649 ( Cr.) .

About Nectar Lifesciences Ltd

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Business segments

  • APIs
  • Formulations
  • Empty hard Gelatin Capsules
  • Phytochemicals

Certifications

  • GMP (Issued by World Health Organization - COPP)
  • ISO 9001:2008 - Quality Management
  • ISO 22000:2005 - Food Safety Management
  • ISO 14001: 2004 - Environment Management Systems
  • ISO 50001: 2011 - Energy Management System
  • OHSAS 18001: 2007 - Occupational Health and Safety
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.